HTFL HEARTFLOW INC

Heartflow to Report Third Quarter 2025 Financial Results on November 12, 2025

Heartflow to Report Third Quarter 2025 Financial Results on November 12, 2025

MOUNTAIN VIEW, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2025 after market close on Wednesday, November 12, 2025. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 12, 2025.

Those interested in listening to the conference call should . Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live and archived webcast of the event will also be available on the “Investor Relations” section of the Heartflow website at .

About Heartflow’s Technology and Research

Backed by ACC/AHA guidelines and over 600 peer-reviewed publications, Heartflow has redefined how clinicians manage care for nearly 500,000 patients worldwide. Our continuous innovation is driven by an unmatched proprietary data pipeline built from over 110 million annotated CTA images. Heartflow’s AI-driven solutions have been extensively validated through clinical evidence in over 100 studies assessing over 365,000 patients. Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 96%. Heartflow’s integrated workflow delivers analysis instantly upon order, enabling clinicians to move from diagnosis to decision without delay. To uphold the highest security and patient-data integrity standards, Heartflow fully complies with leading global security regulations, including HITRUST, SOC2 Type 2, GDPR, HIPAA, CCPA, ISO 13485, and ISO 27001.

About Heartflow, Inc.

Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at .

Investor Contact

Nick Laudico

Media Contact

Elliot Levy



EN
23/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on HEARTFLOW INC

 PRESS RELEASE

Heartflow to Report Third Quarter 2025 Financial Results on November 1...

Heartflow to Report Third Quarter 2025 Financial Results on November 12, 2025 MOUNTAIN VIEW, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2025 after market close on Wednesday, November 12, 2025. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 12, 2025. Those interested in listening to the conference call should . Once registered, participan...

 PRESS RELEASE

New Heartflow PCI Navigator to Equip Interventional Cardiologists with...

New Heartflow PCI Navigator to Equip Interventional Cardiologists with Pre-procedural Insights to Enable PCI Planning PLAN CALCIUM study to be presented at TCT 2025 conference highlights how AI-powered plaque analysis can inform lesion preparation and calcium modification planning NAVIGATE-PCI registry to enroll approximately 2,500 patients across approximately 30 sites to evaluate the impact of CT-guided PCI planning in real-world practice MOUNTAIN VIEW, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery...

 PRESS RELEASE

Heartflow Announces FDA 510(k) Clearance and Launch of Next Generation...

Heartflow Announces FDA 510(k) Clearance and Launch of Next Generation Heartflow Plaque Analysis Platform AI-Powered Heartflow Plaque Analysis to be Covered by Cigna Health Plans Nationwide MOUNTAIN VIEW, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Next Gen algorithm and the platform is now available. The technology features an updated algorithm, vastly expanded nomogram, and advanced 3D color-coded v...

 PRESS RELEASE

Heartflow to Participate in the Morgan Stanley 23rd Annual Global Heal...

Heartflow to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference MOUNTAIN VIEW, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference. The fireside chat will take place on Wednesday, September 10, 2025, at 6:15 a.m. PT / 9:15 a.m. ET. A live and archived version of the fireside chat will be available on the Investor Relatio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch